Vasoactive intestinal peptide (VIP) induces c-fos expression in LNCaP prostate cancer cells through a mechanism that involves Ca2+ signalling. Implications in angiogenesis and neuroendocrine differentiation

Biochim Biophys Acta. 2005 Jun 30;1744(2):224-33. doi: 10.1016/j.bbamcr.2005.04.009.

Abstract

The effect of vasoactive intestinal peptide (VIP) on intracellular Ca(2+) levels and its relationship with the expression of c-fos and vascular endothelial growth factor (VEGF) as well as with neuroendocrine (NE) differentiation were investigated in human prostate LNCaP cells. VIP induced the expression of c-fos mRNA as studied by reverse transcription polymerase chain reaction (RT-PCR). It was accompanied by VIP stimulation of c-fos protein synthesis, as measured by Western blot analysis. VIP enhanced intracellular Ca(2+) levels as evaluated using the calcium probe fura-2. VIP regulation of c-fos expression depended on [Ca(2+)](i) concentration since the intracellular calcium chelator BAPTA/AM decreased c-fos expression (both mRNA and protein) to basal levels. As shown by means of real-time RT-PCR, VIP stimulated VEGF mRNA expression: the effect was inhibited by 40% in the presence of curcumin (an inhibitor of AP-1 binding), and it was dependent on Ca(2+) since BAPTA/AM inhibited this VIP action by 43%. Similar observations were made on the effects of BAPTA/AM and curcumin on VIP stimulation of VEGF protein expression. Simultaneous treatment of cells with the protein kinase A inhibitor H89 and BAPTA/AM completely blocked this VIP effect, whereas each agent alone led only to a partial inhibition. In addition, the calcium chelator blocked by 37% the ability of VIP to induce NE cell differentiation as estimated by the observation of neurite development. These features support a VIP signalling pathway that could be mediated through both cAMP and [Ca(2+)](i) increase in prostate LNCaP cancer cells. Moreover, our data suggest the implication of c-Fos on the induction of the main angiogenic factor VEGF since the promoter region of the VEGF gene possesses AP-1 (i.e., c-Fos/c-Jun heterodimer) response elements. This feature represents a link between the nuclear oncogene c-fos, angiogenesis and NE differentiation by means of an initiating signal upon VIP receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / metabolism
  • Calcium Signaling / drug effects*
  • Cell Differentiation / drug effects
  • Cell Line, Tumor
  • Chelating Agents / pharmacology
  • Cyclic AMP / metabolism
  • Drug Interactions
  • Egtazic Acid / analogs & derivatives*
  • Egtazic Acid / pharmacology
  • Gene Expression Regulation / drug effects*
  • Humans
  • Isoquinolines / pharmacology
  • Male
  • Neuropeptides / metabolism
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-fos / drug effects*
  • Proto-Oncogene Proteins c-fos / genetics*
  • RNA, Messenger / drug effects
  • Sulfonamides / pharmacology
  • Vascular Endothelial Growth Factor A / metabolism
  • Vasoactive Intestinal Peptide / pharmacology*

Substances

  • Chelating Agents
  • Isoquinolines
  • Neuropeptides
  • Proto-Oncogene Proteins c-fos
  • RNA, Messenger
  • Sulfonamides
  • Vascular Endothelial Growth Factor A
  • Vasoactive Intestinal Peptide
  • Egtazic Acid
  • Cyclic AMP
  • 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Calcium